Alex Aliper
Overview
Explore the profile of Alex Aliper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veviorskiy A, Mkrtchyan G, Osipov A, Izumchenko E, Ozerov I, Aliper A, et al.
Aging (Albany NY)
. 2025 Feb;
17(2):550-562.
PMID: 40015963
Radiotherapy is a crucial treatment option for various cancers. However, the results of radiotherapy can vary widely across different cancer types and even among patients with the same type of...
2.
Tang Q, Xiao D, Veviorskiy A, Xin Y, Lok S, Pulous F, et al.
Aging Dis
. 2025 Feb;
PMID: 39965245
Assessing impact on the hallmarks of aging has emerged as a novel method for prioritizing dual-purpose longevity therapeutic targets and developing drugs simultaneously targeting aging and disease. Cellular senescence, a...
3.
Lu H, Sun D, Wang Z, Cui H, Min L, Zhang H, et al.
J Med Chem
. 2025 Feb;
68(4):4148-4167.
PMID: 39948720
Cyclin-dependent kinases 12 and 13 (CDK12/13) safeguard genomic integrity by preferentially regulating gene expression in the DNA damage response (DDR). The CDK12/13-mediated upregulation of DDR genes and pathways significantly contributes...
4.
Wang Y, Zhang Y, Liu J, Zhao J, Wang C, Meng F, et al.
J Med Chem
. 2025 Jan;
68(3):3886-3899.
PMID: 39885813
Fibroblast growth factor receptors (FGFRs) are established oncogenic drivers in various solid tumors. However, the approved FGFR inhibitors face challenges with acquired resistance and dose-limiting adverse effects associated with FGFR1/4...
5.
Ghazi Vakili M, Gorgulla C, Snider J, Nigam A, Bezrukov D, Varoli D, et al.
Nat Biotechnol
. 2025 Jan;
PMID: 39843581
We introduce a quantum-classical generative model for small-molecule design, specifically targeting KRAS inhibitors for cancer therapy. We apply the method to design, select and synthesize 15 proposed molecules that could...
6.
Zhang M, Ding X, Cao Z, Yang Y, Ding X, Cai X, et al.
J Med Chem
. 2025 Jan;
68(2):1940-1955.
PMID: 39787362
Protein arginine methyltransferase 5 (PRMT5), which catalyzes the symmetric dimethylation of arginine residues on target proteins, plays a critical role in gene expression regulation, RNA processing, and signal transduction. Aberrant...
7.
Yang T, Ding X, McMichael E, Pun F, Aliper A, Ren F, et al.
J Cheminform
. 2024 Dec;
16(1):143.
PMID: 39716240
Cardiotoxicity, particularly drug-induced arrhythmias, poses a significant challenge in drug development, highlighting the importance of early-stage prediction of human ether-a-go-go-related gene (hERG) toxicity. hERG encodes the pore-forming subunit of the...
8.
Fu Y, Ding X, Zhang M, Feng C, Yan Z, Wang F, et al.
Nat Biotechnol
. 2024 Dec;
PMID: 39663371
Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we...
9.
Peng J, Ding X, Chen C, Zhao P, Ding X, Zhang M, et al.
J Med Chem
. 2024 Nov;
67(23):21520-21544.
PMID: 39585942
Hematopoietic progenitor kinase 1 (HPK1) has emerged as an attractive target for immunotherapy due to its critical role in T cell activation and proliferation. The major challenge in developing HPK1...
10.
Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors
Peng J, Ding X, Chen C, Shih P, Meng Q, Ding X, et al.
ACS Med Chem Lett
. 2024 Nov;
15(11):2032-2041.
PMID: 39563821
Hematopoietic progenitor kinase 1 (HPK1) negatively affects T cell activation and proliferation and is a promising target for immunotherapy. Although HPK1 inhibitors have shown promising efficacy in preclinical models, none...